ATE191145T1 - Hydralazin zur topischen behandlung von glaukom - Google Patents

Hydralazin zur topischen behandlung von glaukom

Info

Publication number: ATE191145T1
Authority: AT; Austria
Prior art keywords: glaucoma; hydralazine; topical treatment; site; hydrocephalus
Prior art date: 1987-01-23

Application number

AT93202327T

Other languages

English (en)

Inventor

James A Nathanson

Original Assignee

Gen Hospital Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-01-23

Filing date

1988-01-22

Publication date

2000-04-15

1988-01-22 Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp

2000-04-15 Application granted granted Critical

2000-04-15 Publication of ATE191145T1 publication Critical patent/ATE191145T1/de

Links

208000010412 Glaucoma Diseases 0.000 title abstract 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 title 2
229960002474 hydralazine Drugs 0.000 title 1
230000000699 topical effect Effects 0.000 title 1
230000004064 dysfunction Effects 0.000 abstract 2
239000012530 fluid Substances 0.000 abstract 2
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
206010030113 Oedema Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 abstract 1
208000003906 hydrocephalus Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Zoology (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT93202327T 1987-01-23 1988-01-22 Hydralazin zur topischen behandlung von glaukom ATE191145T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US640587A	1987-01-23	1987-01-23

Publications (1)

Publication Number	Publication Date
ATE191145T1 true ATE191145T1 (de)	2000-04-15

Family

ID=21720700

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93202327T ATE191145T1 (de)	1987-01-23	1988-01-22	Hydralazin zur topischen behandlung von glaukom

Country Status (6)

Country	Link
EP (2)	EP0583821B1 (de)
JP (1)	JP2845913B2 (de)
AT (1)	ATE191145T1 (de)
CA (1)	CA1319099C (de)
DE (1)	DE3856401D1 (de)
WO (1)	WO1988005306A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4975428A (en) *	1988-05-31	1990-12-04	Iolab Corporation	Treatment of glaucoma using phosphodiesterase inhibitors
US5204327A (en) *	1988-11-18	1993-04-20	Ashi Kasei Kogyo Kabushiki Kaisha	Treatment of cerebral edema with anp pharmaceutical compositions
US5175161A (en) *	1989-04-06	1992-12-29	Sankyo Company, Limited	Occular hypotensive agents
ES2080137T3 (es) *	1989-06-29	1996-02-01	Univ Washington	Composicion oftalmica.
WO1991002810A1 (en)	1989-08-09	1991-03-07	The Children's Medical Center Corporation	Nmda oxidizing agents for protecting neurons from injury
US5455279A (en) *	1991-04-19	1995-10-03	The Children's Medical Center Corporation	Regimen method of mediating neuronal damage using nitroglycerine
US6071876A (en) *	1991-04-19	2000-06-06	Children's Medical Center Corporation	Method of preventing NMDA receptor complex-mediated neuronal damage
US5922773A (en) *	1992-12-04	1999-07-13	The Children's Medical Center Corp.	Glaucoma treatment
US5597809A (en) *	1994-06-23	1997-01-28	Massachusetts Eye & Ear Infirmary	Treatment of optic neuritis
US5602143A (en) *	1994-12-08	1997-02-11	Allergan	Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
DE69531506T2 (de) *	1994-12-13	2004-06-24	Euroceltique S.A.	Arylthioxanthine
US6248746B1 (en)	1998-01-07	2001-06-19	Euro-Celtique S.A.	3-(arylalkyl) xanthines
DE19903087A1 (de) *	1999-01-27	2000-08-10	Forssmann Wolf Georg	Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
US6482854B1 (en)	1999-03-25	2002-11-19	Massachusetts Eye And Ear Infirmary	Glaucoma treatment
GB0107033D0 (en) *	2001-03-21	2001-05-09	Chumas Paul D	Method and composition
CA2905585C (en)	2001-03-29	2020-02-18	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
US7476662B2 (en)	2001-06-12	2009-01-13	Janssen Pharmaceutica N.V.	Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine
FR2851247B1 (fr)	2003-02-19	2007-06-29	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de pathologies degeneratives oculaires
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100221329A1 (en)	2008-12-03	2010-09-02	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase c agonists and methods of use
WO2010098839A1 (en) *	2009-02-25	2010-09-02	Intra-Cellular Therapies, Inc.	Pde 1 inhibitors for ophthalmic disorders
ES2582309T3 (es) *	2010-08-03	2016-09-12	G. Pohl-Boskamp Gmbh & Co. Kg	Uso de trinitrato de glicerilo para el tratamiento de edema traumático
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012037380A2 (en)	2010-09-15	2012-03-22	Synergy Pharmaceuticals Inc.	Formulations of guanylate cyclase c agonists and methods of use
WO2012113564A1 (en)	2011-02-25	2012-08-30	G. Pohl-Boskamp Gmbh & Co. Kg	Stabilized granules containing glyceryl trinitrate
PL2668947T3 (pl)	2012-05-31	2017-06-30	G. Pohl-Boskamp Gmbh & Co. Kg	Indukcja arteriogenezy donorem NO, takim jak nitrogliceryna
US9248099B2 (en)	2012-05-31	2016-02-02	Desmoid Aktiengesellschaft	Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
WO2013188217A1 (en) *	2012-06-11	2013-12-19	Macuclear, Inc.	Therapeutic formulation and methods of treatment
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
EP2878310B1 (de)	2013-11-29	2017-01-11	G. Pohl-Boskamp GmbH & Co. KG	Sprühbare wässrige Zusammensetzung mit Nitroglycerin
WO2015152416A1 (ja) *	2014-04-04	2015-10-08	国立大学法人東北大学	眼圧降下剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4496544A (en) *	1983-11-10	1985-01-29	Washington University	Atrial Peptides
US4508712A (en) *	1984-01-10	1985-04-02	Washington University	Atrial peptide
WO1985004872A1 (en) *	1984-04-24	1985-11-07	The Salk Institute For Biological Studies	Atrial peptide analogs
US4696932A (en) *	1984-10-26	1987-09-29	The United States Of America As Represented By The Department Of Health And Human Services	Biologically-active xanthine derivatives
US4762851A (en) *	1985-11-29	1988-08-09	Merck & Co., Inc.	Pyroglutamic acid esters used as dermal penetration enhancers for drugs
DE3614833A1 (de) *	1986-01-16	1987-07-23	Hoechst Ag	Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung

1988
- 1988-01-22 EP EP93202327A patent/EP0583821B1/de not_active Expired - Lifetime
- 1988-01-22 CA CA000557141A patent/CA1319099C/en not_active Expired - Fee Related
- 1988-01-22 JP JP63501881A patent/JP2845913B2/ja not_active Expired - Lifetime
- 1988-01-22 WO PCT/US1988/000168 patent/WO1988005306A1/en not_active Ceased
- 1988-01-22 EP EP19880901976 patent/EP0341264A4/en not_active Withdrawn
- 1988-01-22 DE DE3856401T patent/DE3856401D1/de not_active Expired - Lifetime
- 1988-01-22 AT AT93202327T patent/ATE191145T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
JPH02502635A (ja)	1990-08-23
CA1319099C (en)	1993-06-15
WO1988005306A1 (en)	1988-07-28
EP0341264A1 (de)	1989-11-15
JP2845913B2 (ja)	1999-01-13
DE3856401D1 (de)	2000-05-04
EP0583821B1 (de)	2000-03-29
EP0583821A1 (de)	1994-02-23
EP0341264A4 (en)	1991-03-20

Legal Events

Date	Code	Title	Description
2000-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE3856401D1 (de)	2000-05-04	Hydralazin zur topischen Behandlung von Glaukom
ATE88097T1 (de)	1993-04-15	Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
DE69328474D1 (de)	2000-05-31	Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
DE3855891D1 (de)	1997-05-28	Gerät zur Behandlung mittels Zentrifugieren
DE3872012D1 (de)	1992-07-23	Verfahren fuer die behandlung von abwasser aus photoprozessen mittels konzentration durch verdampfen.
ATE33098T1 (de)	1988-04-15	Celiprolol zur behandlung von glaukom.
DE4391418T1 (de)	1994-05-05	Vorrichtung zur elektrochemischen Behandlung von Wasser
DE68912387D1 (de)	1994-03-03	Verfahren und Vorrichtung zur Behandlung von Wasser durch wechselnde elektromagnetische Frequenzen.
DE68926728D1 (de)	1996-08-01	Makrolidzusammensetzungen zur Behandlung von Störungen des Bewegungsvermögens des Magendarmtraktes
ATE92061T1 (de)	1993-08-15	Substituierte tetraline, chromane und verwandte verbindungen fuer die behandlung von asthma, arthritis und verwandte krankheiten.
DE3788057D1 (de)	1993-12-09	Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE69022269D1 (de)	1995-10-19	Verfahren zur thermischen Behandlung von Silizium.
DE3481277D1 (de)	1990-03-15	Vorrichtung zur behandlung von gas-fluessigkeitsgemischen.
ATA456682A (de)	1987-12-15	Vorrichtung zum herstellen von damenbinden
DE3888056D1 (de)	1994-04-07	Oxadiazolyl-azabicycloheptane zur Behandlung von seniler Demenz.
AT378945B (de)	1985-10-25	Verfahren zur behandlung von soleabschlaemmungen
DE69200684D1 (de)	1994-12-22	Vorrichtung zur thermischen Behandlung von laufenden Garnen.
AT383123B (de)	1987-05-25	Verfahren zur herstellung von neuen (+)-catechin- alpha- monohydrat
DE3681642D1 (de)	1991-10-31	Benzopyran-verbindungen zur behandlung von inkontinenz.
BE802606A (fr)	1974-01-21	Procede d'epuration des eaux residuaires sulfurees
DE3875881D1 (de)	1992-12-17	Vorrichtung fuer die behandlung von abwasser aus photoprozessen.
DE60108130D1 (de)	2005-02-03	Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE3875016D1 (de)	1992-11-05	Therapeutikum zur behandlung von aids.
DE69327207D1 (de)	2000-01-13	Tryptamine zur Behandlung von Störungen der circadianen Rhythmik
EP1056458A4 (de)	2001-06-20	Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen